TTPH Tetraphase Pharmaceuticals Inc.

1.04
-0.02  -2%
Previous Close 1.06
Open 1.06
Price To Book 0.7
Market Cap 55848000
Shares 53,700,000
Volume 220,105
Short Ratio
Av. Daily Volume 631,658

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial did not meet endpoints September 2015. Additional Phase 3 trial also did not meet primary endpoints - noted February 13, 2018.
Eravacycline (TP-434) - IGNITE3
cUTI - complicated urinary tract infections
FDA approval announced August 27, 2018.
Eravacycline (TP-434) - IGNITE4
cIAI (complicated intra-abdominal infections)
Phase 1 trial complete.
TP-271
Community-acquired bacterial pneumonia (CABP)
Phase 1 bronchopulmonary disposition trial to be completed 2H 2019.
TP-6076

Latest News

  1. Tetraphase Pharmaceuticals to Present Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases
  2. Robbins Arroyo LLP: Tetraphase Pharmaceuticals, Inc. (TTPH) Accused of Misleading Shareholders
  3. Tetraphase Pharmaceuticals Presents Preclinical Data on TP-2846, a Novel Drug Candidate for Acute Myeloid Leukemia
  4. Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
  5. Edited Transcript of TTPH earnings conference call or presentation 14-Mar-19 8:30pm GMT
  6. Tetraphase Pharmaceuticals (TTPH) Q4 2018 Earnings Conference Call Transcript
  7. Tetraphase: 4Q Earnings Snapshot
  8. Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Achievements and Key 2019 Milestones
  9. Tetraphase Pharmaceuticals, Inc. to Host Earnings Call
  10. Tetraphase Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Financial Results Conference Call
  11. Tetraphase Pharmaceuticals to Present Data on Preclinical Activity of TP-2846 in Acute Myeloid Leukemia
  12. Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Tetraphase Pharmaceuticals, Inc. (TTPH) and Encourages TTPH Investors to Contact the Firm
  13. Robbins Arroyo LLP: Shareholders Allege That Tetraphase Pharmaceuticals, Inc. (TTPH) Misled Shareholders
  14. New Research: Key Drivers of Growth for Tetraphase Pharmaceuticals, Olympic Steel, Belden, KAR Auction Services, BWX Technologies, and Sparton — Factors of Influence, Major Initiatives and Sustained Production
  15. Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference
  16. Report: Exploring Fundamental Drivers Behind Resonant, Constellation Brands, Masimo, Tetraphase Pharmaceuticals, LivaNova, and Penumbra — New Horizons, Emerging Trends, and Upcoming Developments
  17. Edited Transcript of TTPH earnings conference call or presentation 8-Nov-18 9:30pm GMT
  18. Tetraphase Pharmaceuticals (TTPH) Reports Q3 Loss, Lags Revenue Estimates
  19. Tetraphase Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update